3.70

2.21% 0.08

After Hours: 3.69 -0.01 -0.27%

Zentalis Pharmaceuticals Inc (ZNTL)

Overview News Price History Option Chain Financials Why ZNTL Down? Discussions Forecast

Zentalis Pharmaceuticals Inc stock is traded at $3.70, with a volume of 575.38K. It is up +2.21% in the last 24 hours and up +1.93% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Previous Close:

$3.62

Open:

$3.62

24h Volume:

575.38K

Relative Volume:

0.30

Market Cap:

$263.39M

Revenue:

$26.87M

Net Income/Loss:

$-124.13M

P/E Ratio:

-2.1291

EPS:

-1.7378

Net Cash Flow:

$-125.60M

1W Performance:

+5.11%

1M Performance:

+1.93%

6M Performance:

+160.56%

1Y Performance:

+168.12%

1-Day Range:

$3.595

$3.75

1-Week Range:

$3.47

$4.055

52-Week Range:

$1.13

$6.95

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name

Zentalis Pharmaceuticals Inc

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

(858) 263-4333

Address

10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY

Employee

106

Twitter

@ZentalisP

Next Earnings Date

2026-08-05

Latest SEC Filings

ZNTL's Discussions on Twitter

Compare ZNTL vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZNTL Zentalis Pharmaceuticals Inc	3.70	263.39M	26.87M	-124.13M	-125.60M	-1.7378
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-26	Resumed	Wells Fargo	Equal Weight
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral
Jun-20-24	Downgrade	UBS	Buy → Neutral
Jun-18-24	Downgrade	Jefferies	Buy → Hold
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight
Oct-07-21	Resumed	Jefferies	Buy
Sep-30-21	Initiated	Stifel	Buy
Sep-29-21	Initiated	Oppenheimer	Outperform
May-21-21	Initiated	UBS	Buy
Jan-20-21	Initiated	Wedbush	Outperform
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight
Aug-27-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Guggenheim	Buy
Apr-28-20	Initiated	Jefferies	Buy
Apr-28-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Initiated	SVB Leerink	Outperform

View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

Jun 18, 2026

Zentalis Shareholders Back Directors, Auditors and Executive Pay - TipRanks

Jun 18, 2026

Zentalis (ZNTL) director awarded 57,100 RSUs, boosting holdings to 307,521 shares - Stock Titan

Jun 18, 2026

RSU grant boosts Zentalis (ZNTL) director Jan Skvarka's holdings - Stock Titan

Jun 18, 2026

Zentalis Pharmaceuticals (ZNTL) director granted 57,100 restricted stock units - Stock Titan

Jun 18, 2026

Zentalis (ZNTL) director Enoch Kariuki granted 57,100 restricted stock units - Stock Titan

Jun 18, 2026

Zentalis Pharmaceuticals (ZNTL) director awarded 57,100 RSUs - Stock Titan

Jun 18, 2026

Zentalis (ZNTL) investors elect directors and ratify Ernst & Young at 2026 meeting - Stock Titan

Jun 18, 2026

Jun 17, 2026